Third, although we demonstrated that both si-FIBCD1 and sh-FIBCD1 were strong inhibitors of BC cell malignancy, we could not exclude the possibility of off-target effects, where si/shRNA might unintentionally silence non-targeted transcripts with partial sequence complementarity. This evidence concerns the gene FIBCD1 and breast cancer.